In the STEP2 focusing on 1,210 patients with obesity or overweight and T2D, average weight loss with semaglutide 2.4 mg therapy was 6.2% compared to the placebo [47]
Its effect was associated with a signicant decrease in oxidative stress parameters and likely maintained NO system function, providing that BPC 157 interacted with eNOS and COX2 gene expression in a particular way and counteracted the noxious effect of the NOS-blocker, L-NAME
However, understanding the optimal timing for its intake is essential to fully leveraging its benefits
accessed on 5 December 2025 [18]) indicating expression of both mRNA and protein across multiple tissue types including brain, liver, kidney, heart, pancreas and gastrointestinal tissues
After bariatric or stomach surgery, resuming GLP-1 therapy requires extra care because your new stomach anatomy affects medication absorption and side effect risk